Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials

• Published in: European heart journal
• Main Authors: Schnabel, Renate B, Benezet-Mazuecos, Juan, Becher, Nina, McIntyre, William F, Fierenz, Alexander, Lee, Shun Fu, Goette, Andreas, Atar, Dan, Bertaglia, Emanuele, Benz, Alexander P, Chlouverakis, Gregory, Birnie, David H, Dichtl, Wolfgang, Blomstrom-Lundqvist, Carina, Camm, A John, Erath, Julia W, Simantirakis, Emmanuel, Kutyifa, Valentina, Lip, Gregory Y H, Mabo, Philippe, Marijon, Eloi, Rivard, Lena, Schotten, Ulrich, Alings, Marco, Sehner, Susanne, Toennis, Tobias, Linde, Cecilia, Vardas, Panos, Granger, Christopher B, Zapf, Antonia, Lopes, Renato D, Healey, Jeff S, Kirchhof, Paulus
• Format: Journal Article
• Language: English
• Published: England Oxford University Press (OUP) 02.09.2024
• Subjects: Cardiology and cardiovascular system; Human health and pathology; Life Sciences; Medicin och hälsovetenskap; device-detected atrial fibrillation; atrial fibrillation; oral anticoagulation; stroke; trial
• ISSN: 0195-668X; 1522-9645; 1522-9645
• DOI: 10.1093/eurheartj/ehae596

The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.